Screener
Zymeworks ZYME Bispecific Antibodies — Research and development collaborations (note 11)
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Zymeworks’s 10-K, filed March 2, 2026.
- Filed
- Mar 2, 2026, 6:28 AM EST
- Fiscal year
- FY2025
- Accession
- 0001937653-26-000015
From contract inception to the termination of 2016 Daiichi Collaboration agreement as defined below, the Company has received an upfront technology access fee payment of $2.0 million and research and commercial option related payments totaling $4.5 million.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Zymeworks's bispecific antibodies — research and development collaborations (note 11)?
- Zymeworks (ZYME) reported bispecific antibodies — research and development collaborations (note 11) of $2M in Q4 2025.
- What does bispecific antibodies — research and development collaborations (note 11) mean?
- This metric represents the revenue recognized from strategic partnerships and collaborative agreements specifically related to the development of bispecific antibody therapeutic platforms. It reflects the company's ability to monetize its proprietary technology through external funding, milestone payments, or shared development costs with pharmaceutical partners. This figure serves as a key indicator of the commercial validation and market interest in the company's specialized biotherapeutic engineering capabilities.
Ask your AI about Zymeworks's bispecific antibodies — research and development collaborations (note 11).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude